EDGAR·FLOW

Akebia Therapeutics, Inc. — Form 8-K

Filed November 16, 2026 · analyzed by the 8-K Agent
8-K — Neutral significance 48/100
What the filing says
Akebia Therapeutics entered into a senior secured term loan with Symbiotic Capital on November 12, 2026, consisting of an initial $60 million tranche (fully funded) plus an optional $80 million incremental tranche at Symbiotic's discretion. Proceeds from the initial tranche were used to fully repay the $55 million BlackRock loan facility. The new facility carries a 60-month maturity with interest-only for 60 months (variable rate: greater of WSJ Prime + 4.5% or 11.5%). Management reaffirmed at least two years of cash runway.
Why this rating

Refinancing replaces maturing debt; $60M equals ~6% of market cap. Non-dilutive but higher interest rates signal tighter credit access. Cash runway reaffirmation provides stability.

View original filing on SEC.gov ↗ AKBA · stock on Yahoo Finance ↗

See more from November 16, 2026.

EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.